Peyronie’s disease is more common than Dupuytren’s – 3 to 9 percent of the population – and shares a similar biology and genetic predisposition. Progress in the treatment of Peyronie’s will benefit that of Dupuytren’s and vice versa. Taken in this context, these two articles by Hellstrom from 2000 and 2009 are very thought provoking. Animal model? Oral, topical or intralesional medication? Radiation? Shockwave treatment? Could these be applied to Dupuytren’s?